Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Small Interfering | 16 | 2024 | 855 | 1.770 |
Why?
|
| Huntingtin Protein | 7 | 2024 | 138 | 1.280 |
Why?
|
| Central Nervous System | 3 | 2024 | 192 | 0.960 |
Why?
|
| Huntington Disease | 4 | 2024 | 146 | 0.550 |
Why?
|
| RNA Interference | 4 | 2024 | 592 | 0.440 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1542 | 0.420 |
Why?
|
| Neurons | 3 | 2019 | 861 | 0.300 |
Why?
|
| Oligonucleotides | 2 | 2021 | 210 | 0.290 |
Why?
|
| Cholesterol | 2 | 2018 | 255 | 0.260 |
Why?
|
| Gene Silencing | 7 | 2024 | 379 | 0.250 |
Why?
|
| Mice | 11 | 2024 | 10317 | 0.240 |
Why?
|
| Animals | 15 | 2024 | 19739 | 0.220 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 18 | 0.220 |
Why?
|
| Organophosphonates | 2 | 2021 | 21 | 0.190 |
Why?
|
| Endocytosis | 2 | 2019 | 148 | 0.190 |
Why?
|
| Vitiligo | 1 | 2023 | 121 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 70 | 0.180 |
Why?
|
| Synaptic Vesicles | 1 | 2019 | 26 | 0.170 |
Why?
|
| Genetic Therapy | 3 | 2021 | 742 | 0.160 |
Why?
|
| Corpus Striatum | 1 | 2019 | 93 | 0.160 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 5 | 2018 | 254 | 0.160 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 81 | 0.150 |
Why?
|
| Extracellular Vesicles | 1 | 2018 | 43 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 5 | 2024 | 3215 | 0.140 |
Why?
|
| Vinyl Compounds | 1 | 2017 | 5 | 0.140 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2018 | 87 | 0.140 |
Why?
|
| Triazoles | 1 | 2017 | 52 | 0.140 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 48 | 0.130 |
Why?
|
| Genome, Human | 1 | 2018 | 221 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2019 | 1465 | 0.130 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 105 | 0.130 |
Why?
|
| Guanabenz | 1 | 2015 | 3 | 0.130 |
Why?
|
| Exosomes | 1 | 2016 | 42 | 0.130 |
Why?
|
| Endosomes | 1 | 2016 | 170 | 0.120 |
Why?
|
| HeLa Cells | 4 | 2018 | 530 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 193 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 311 | 0.120 |
Why?
|
| Mutation | 2 | 2019 | 2466 | 0.110 |
Why?
|
| Gene Editing | 1 | 2018 | 301 | 0.110 |
Why?
|
| Apolipoproteins E | 2 | 2024 | 98 | 0.110 |
Why?
|
| Liver | 3 | 2024 | 785 | 0.100 |
Why?
|
| Alleles | 2 | 2022 | 417 | 0.090 |
Why?
|
| Humans | 13 | 2024 | 60081 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2018 | 2095 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2018 | 284 | 0.070 |
Why?
|
| Biological Transport | 2 | 2016 | 287 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 2 | 2015 | 73 | 0.060 |
Why?
|
| Antagomirs | 1 | 2024 | 5 | 0.060 |
Why?
|
| Acetylgalactosamine | 1 | 2024 | 10 | 0.060 |
Why?
|
| Janus Kinase 1 | 1 | 2023 | 10 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2074 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2023 | 108 | 0.050 |
Why?
|
| Gene Expression | 2 | 2016 | 808 | 0.050 |
Why?
|
| Chemical Engineering | 1 | 2022 | 9 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 20 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2023 | 222 | 0.050 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2021 | 12 | 0.050 |
Why?
|
| RNAi Therapeutics | 1 | 2021 | 12 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2021 | 79 | 0.050 |
Why?
|
| Sheep | 1 | 2021 | 168 | 0.050 |
Why?
|
| Fibrosis | 1 | 2021 | 151 | 0.050 |
Why?
|
| Triglycerides | 1 | 2021 | 242 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2022 | 416 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2019 | 34 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 651 | 0.040 |
Why?
|
| Mannitol | 1 | 2018 | 14 | 0.040 |
Why?
|
| Propylene Glycols | 1 | 2018 | 9 | 0.040 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 34 | 0.040 |
Why?
|
| Aptamers, Nucleotide | 1 | 2018 | 18 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2018 | 59 | 0.040 |
Why?
|
| Phosphorylcholine | 1 | 2018 | 41 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 560 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2024 | 617 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2018 | 104 | 0.040 |
Why?
|
| Astrocytes | 1 | 2018 | 116 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2017 | 25 | 0.040 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2017 | 67 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 92 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2017 | 135 | 0.030 |
Why?
|
| Cyclophilins | 1 | 2016 | 12 | 0.030 |
Why?
|
| RNA Stability | 1 | 2017 | 94 | 0.030 |
Why?
|
| COS Cells | 1 | 2016 | 175 | 0.030 |
Why?
|
| Transferrin | 1 | 2016 | 67 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 234 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 585 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 306 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2015 | 57 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 399 | 0.030 |
Why?
|
| Kidney | 1 | 2017 | 397 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1111 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 860 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 893 | 0.030 |
Why?
|
| Rats | 1 | 2018 | 1908 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 375 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 549 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 1191 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2017 | 1139 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2018 | 818 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1565 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 1485 | 0.020 |
Why?
|
| Female | 2 | 2018 | 31226 | 0.020 |
Why?
|
| Male | 1 | 2024 | 27951 | 0.010 |
Why?
|